Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10166230-B2
Publication Date
2019-01-01
Expiration Date
Abstract
The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.
Core Innovation
The invention relates to a method for the treatment of vasomotor symptoms associated with menopause by administering to a patient in need thereof a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate or solvate thereof. The vasomotor symptoms are selected from night sweats, mood swings, and irritability.
The method is directed to vasomotor symptoms occurring in connection with menopause and menopausal transition. The described menopausal states include naturally occurring menopause, iatrogenic induced menopause, and surgically induced menopause.
The disclosure further encompasses pharmaceutical formulations and composition forms of flibanserin, including flibanserin hydrochloride, optionally as free base, salts, hydrates, or solvates. Example dosage forms include tablets, coated tablets, capsules, injection solution, suppositories, and film-coated tablets, together with stated dosing ranges expressed as 0.1–400 mg/day, including preferred ranges.
Claims Coverage
Independent claim clm-00001 contains 2 inventive features.
Treatment of menopause-associated vasomotor symptoms with flibanserin
A method for the treatment of vasomotor symptoms associated with menopause by administering to a patient in need a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate or solvate thereof.
Selected vasomotor symptom set
The vasomotor symptoms are selected from the group consisting of night sweats, mood swings, and irritability.
The claim coverage centers on flibanserin, including pharmacologically acceptable acid addition salt, hydrate, or solvate, administered as a therapeutically effective amount to treat vasomotor symptoms associated with menopause, with the symptoms limited to night sweats, mood swings, and irritability.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?